Teladoc Health (TDOC) Unveils Solution to Ease Weight Loss
Teladoc Health, Inc. TDOC recently enhanced its weight management capabilities in a bid to offer a personalized health and medical care program to keep an eye on minimizing care costs related to obesity and promoting healthy weight loss. The new solution will be offered to TDOC’s members via health plans or employers. Its shares gained 0.5% on Mar 8.
The Comprehensive Weight Management solution is devised by a multidisciplinary clinical care squad powered by an extensive provider network of Teladoc Health, which is well-versed in obesity medicine and providing coordinated, member-focused care. Based on comprehensive assistance from experts, the new program pursues an evidence-based, personalized and integrated approach to weight loss, delves into lifestyle changes related to nutrition, activity, sleep and stress, and subsequently, brings about better cardiometabolic health outcomes.
The tailored solution makes use of optional provider-led efficient prescribing, greater member assistance and direct Pharmacy Benefit Manager integration, which in turn, enables plan sponsors and pharmacy benefit managers to better manage and ease the mounting intricacies and expenses linked with obesity management.
This results in the increased efficacy of glucagon-like peptide 1 and other anti-obesity medications. The enhanced solution also brings about improved care coordination with non-Teladoc Health physicians. Meanwhile, it also assures to offer assistance in the form of digitally enabled smart scales, digital meal planning tools and wearable connectivity to bring about better health outcomes. With integrated clinical care, the ulterior motive of the new program remains to address the whole-person health requirements of its members.
The recent move reflects Teladoc Health’s sincere efforts to further solidify its weight management solution in light of rapidly evolving scientific advancements and market needs. Additionally, the initiative can also be termed as a time opportune one because more than 40% of American adults are likely to be obese. This condition, if not checked at the correct time, can give rise to heart disease, stroke, type 2 diabetes and other health complications.
Obese people need to be monitored carefully as the disease witnesses periods of high risk, control and recurrence. This provides a perfect opportunity for Teladoc Health to capitalize on through its tailored weight management program. The lucrativeness of the new solution is expected to fetch higher members to TDOC and subsequently, boost its top line in the days ahead.
Shares of Teladoc Health have lost 28.4% year to date against the industry’s 6.2% growth. TDOC currently carries a Zacks Rank #3 (Hold).
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks in the Medical space are Organon & Co. OGN, The Ensign Group, Inc. ENSG and Chemed Corporation CHE. While Organon currently sports a Zacks Rank #1 (Strong Buy), Ensign Group and Chemed carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Organon’s earnings surpassed the Zacks Consensus Estimate in two of the last four quarters and missed the mark twice, the average surprise being 5.06%. The Zacks Consensus Estimate for OGN’s earnings indicates a rise of 3.6%, while the consensus mark for revenues suggests an improvement of 1% from the corresponding year-ago reported figures.
The consensus estimate for OGN’s 2024 earnings has moved 2.1% north in the past 30 days. Shares of Organon have gained 27.2% year to date.
Ensign Group’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 1.74%. The Zacks Consensus Estimate for ENSG’s 2024 earnings indicates a rise of 12.2% from the year-ago reported figure. The consensus mark for revenues indicates growth of 11.2% from the year-ago reported figure.
The consensus estimate for ENSG’s 2024 earnings has moved 0.6% north in the past seven days. Shares of Ensign Group have gained 9.5% year to date.
Chemed’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed the mark twice, the average surprise being 1.06%. The Zacks Consensus Estimate for CHE’s 2024 earnings indicates a rise of 15.1%, while the consensus mark for revenues suggests an improvement of 5.2% from the corresponding year-ago reported figures.
The Zacks Consensus Estimate for CHE’s 2024 earnings has moved 1.9% north in the past 30 days. Shares of Chemed have rallied 28% year to date.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Chemed Corporation (CHE) : Free Stock Analysis Report
The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report
Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report
Organon & Co. (OGN) : Free Stock Analysis Report
